These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2972366)

  • 21. Natural killer (NK)-like cytotoxic activity of allospecific T cell receptor-gamma,delta+ T cell clones. Distinct receptor-ligand interactions mediate NK-like and allospecific cytotoxicity.
    Koide J; Rivas A; Engleman EG
    J Immunol; 1989 Jun; 142(12):4161-8. PubMed ID: 2470816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB; Itoh K; Balch CM
    J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TGF beta down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells.
    Jin B; Scott JL; Vadas MA; Burns GF
    Immunology; 1989 Apr; 66(4):570-6. PubMed ID: 2541074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
    Ozdemir O; Ravindranath Y; Savaşan S
    J Immunother; 2005; 28(1):44-52. PubMed ID: 15614044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine-induced enhancement of the susceptibility of hairy cell leukaemia lymphocytes to natural killer cell lysis.
    Cordingley FT; Hoffbrand AV; Brenner MK
    Br J Haematol; 1988 Sep; 70(1):37-41. PubMed ID: 3140887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
    Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
    J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.
    Fox BA; Rosenberg SA
    Cancer Immunol Immunother; 1989; 29(3):155-66. PubMed ID: 2786456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assignment of human natural killer (NK)-like cells to the T cell lineage. Single allospecific T cell clones lyse specific or NK-sensitive target cells via distinct recognition structures.
    Moretta A; Pantaleo G; Mingari MC; Melioli G; Moretta L; Cerottini JC
    Eur J Immunol; 1984 Feb; 14(2):121-5. PubMed ID: 6230242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells.
    Burns GF; Triglia T; Werkmeister JA
    J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies of lymphokine-activated killer (LAK) cells. I. Evidence using novel monoclonal antibodies that most human LAK precursor cells share a common surface marker.
    Morris DG; Pross HF
    J Exp Med; 1989 Mar; 169(3):717-36. PubMed ID: 2784480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The heterogeneity of target recognition by lymphokine-activated killer precursor cells.
    Ibayashi Y; Gray JD; Golub SH; Daibo M; Yamaki T; Kawahara T; Kubota T; Hashi K
    Jpn J Cancer Res; 1990 Sep; 81(9):927-35. PubMed ID: 2121694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors.
    Dianzani U; Zarcone D; Pistoia V; Grossi CE; Pileri A; Massaia M; Ferrarini M
    Eur J Immunol; 1989 Jun; 19(6):1037-44. PubMed ID: 2502419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
    Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
    Chong AS; Scuderi P; Grimes WJ; Hersh EM
    J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells.
    Oshimi K; Oshimi Y; Akutsu M; Takei Y; Saito H; Okada M; Mizoguchi H
    Blood; 1986 Oct; 68(4):938-48. PubMed ID: 3489494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunological responses against an autologous human hepatocellular carcinoma cell line.
    Usuda S; Yoshizawa K; Yabu K; Kiyosawa K
    J Gastroenterol Hepatol; 1993; 8(6):517-23. PubMed ID: 8280838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral blood lymphocytes from thermal injury patients are defective in their ability to generate lymphokine-activated killer (LAK) cell activity.
    Klimpel GR; Herndon DH; Stein MD
    J Clin Immunol; 1988 Jan; 8(1):14-22. PubMed ID: 2966807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of CD3- lymphocyte function with an antibody against the IL-2 beta chain receptor: modulation of NK and LAK activity and production of IFN gamma.
    Ortaldo JR; Frey J; Takeshita T; Sugamura K
    Eur Cytokine Netw; 1990; 1(1):27-34. PubMed ID: 2151685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modification of natural killer activity of lymphocytes infiltrating human lung cancers.
    Anderson TM; Ibayashi Y; Holmes EC; Golub SH
    Cancer Immunol Immunother; 1987; 25(1):65-8. PubMed ID: 3109739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.